ATE178357T1 - Nachweismethoden für c-raf-1-genes.5 - Google Patents

Nachweismethoden für c-raf-1-genes.5

Info

Publication number
ATE178357T1
ATE178357T1 AT92920292T AT92920292T ATE178357T1 AT E178357 T1 ATE178357 T1 AT E178357T1 AT 92920292 T AT92920292 T AT 92920292T AT 92920292 T AT92920292 T AT 92920292T AT E178357 T1 ATE178357 T1 AT E178357T1
Authority
AT
Austria
Prior art keywords
raf
genes
detection methods
cancer
determining
Prior art date
Application number
AT92920292T
Other languages
English (en)
Inventor
Ulf R Rapp
Stephen M Storm
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE178357T1 publication Critical patent/ATE178357T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT92920292T 1991-09-16 1992-09-16 Nachweismethoden für c-raf-1-genes.5 ATE178357T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75973891A 1991-09-16 1991-09-16

Publications (1)

Publication Number Publication Date
ATE178357T1 true ATE178357T1 (de) 1999-04-15

Family

ID=25056776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92920292T ATE178357T1 (de) 1991-09-16 1992-09-16 Nachweismethoden für c-raf-1-genes.5

Country Status (7)

Country Link
EP (1) EP0612353B1 (de)
JP (1) JPH08506000A (de)
AT (1) ATE178357T1 (de)
AU (1) AU666336B2 (de)
CA (1) CA2118724C (de)
DE (1) DE69228824T2 (de)
WO (1) WO1993006248A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582995A (en) * 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
KR100211178B1 (ko) * 1994-05-31 1999-07-15 파샬 비. 린네 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
US5981731A (en) * 1994-05-31 1999-11-09 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of B-raf gene expression
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
DE10020138A1 (de) * 2000-04-14 2001-10-31 Ulf R Rapp Nukleinsäure codierend für zumindest eine raf Teilsequenz mit einer MEKK1 Bindungsstelle
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458831A1 (de) * 1989-02-16 1991-12-04 BALAZS, Viktor, Dr. Dr. med. Malignitätstest (krebs-test) mit verwendung von der polymerasekettenreaktion
AU630001B2 (en) * 1989-10-02 1992-10-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A sensitive method for measurement of chimeric transcripts of dna containing translocations
DE69108716T2 (de) * 1990-01-26 1995-08-17 Washington Research Foundation, Seattle, Wash. Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.
WO1991012343A2 (en) * 1990-02-07 1991-08-22 F. Hoffmann-La Roche Ag Detection of point mutations in genes encoding gtp binding proteins
WO1991019006A1 (en) * 1990-06-01 1991-12-12 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce MONOCLONAL ANTIBODIES FOR IDENTIFICATION AND PREPARATION OF raf-1 ONCOPROTEIN

Also Published As

Publication number Publication date
AU2658992A (en) 1993-04-27
DE69228824D1 (de) 1999-05-06
CA2118724A1 (en) 1993-04-01
AU666336B2 (en) 1996-02-08
EP0612353B1 (de) 1999-03-31
DE69228824T2 (de) 1999-12-09
EP0612353A1 (de) 1994-08-31
WO1993006248A1 (en) 1993-04-01
CA2118724C (en) 2002-01-15
JPH08506000A (ja) 1996-07-02

Similar Documents

Publication Publication Date Title
DE69228824D1 (de) NACHWEISMETHODEN FÜR C-Raf-1-GENES.5
ATE123301T1 (de) Gentechnologisch-hergestellte aprotinin-homologe.
DE69842208D1 (de) Vorrichtung für eine isolierte Beckenperfusion
ATE360989T1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
NO873753D0 (no) Periodisk biologisk luftbehandlingsprosess og system for denne.
WO2000052054A3 (en) Antibodies for cancer therapy and diagnosis
IL142824A0 (en) Lipoic acid derivatives and their use in treatment of disease
IT8221820A0 (it) Metodo e sistema per il trattamento extracorporeo del sangue.
DE3873847D1 (de) Behandlungsapparat und -verfahren.
DK0617124T3 (da) Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster
NO970535D0 (no) Behandlingssystem for avgitt blod og metode for å danne regulerte virvelströmforhold
DE69111664D1 (de) Blutpumpe und Apparat für die extracorporale Blutzirkulation.
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
NO953770L (no) Analysemetode
FI933291A0 (fi) Foerfarande foer paovisning av anti-rna-antikroppar
CY1109029T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη ονομαζομενη 85p1b3 χρησιμα στην αγωγη και τον εντοπισμο του καρκινου
CY1107921T1 (el) Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων
IL100527A0 (en) Prescreening of prostate cancer by serum prostatic specific antigen
ITMI922255A0 (it) Metodo perfezionato per la realizzazione di titoli di credito in genere e dispositivo per un corretto riconoscimento della titolarita' degli stessi.
DE69637325D1 (de) Methode für die behandlung einer hepatitisvirusinfektion
SU640002A1 (ru) Скважина
ATE537257T1 (de) Mit iga-nephropathie assoziierte dns
NO870865D0 (no) Fremgangsmaate og apparat for databehandling.
DE69627352D1 (de) Verfahren zur identifizierung personen empfindlich für betahemolytischer streptococci-vermittelter neuropsychiatrischer krankheiten
DE3884391D1 (de) Verfahren zur integrierten onkologischen eingangsuntersuchung und krebstherapie.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee